Halozyme Therapeutics (NASDAQ:HALO) Updates FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY24 guidance to $4.00-$4.20 EPS.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HALO. Piper Sandler boosted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a report on Monday, December 30th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Price Performance

HALO opened at $51.19 on Wednesday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53. The stock’s 50 day simple moving average is $50.10 and its 200 day simple moving average is $54.00. The firm has a market cap of $6.51 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.70% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.